
Tackling the shortage of high-quality data that most constrains AI in drug discovery, with hundreds of thousands of in vitro measurements across 100 industrially important protein targets
SyntheticGestalt KK (headquarters: Minato-ku, Tokyo; CEO: Koki Shimada) announces that on 7 August 2026 Enamine Ltd. (headquarters: Kyiv, Ukraine; CEO: Andrey Tolmachov) announced a collaboration between the two companies to build the world’s largest in vitro-validated AI drug discovery data ecosystem. SyntheticGestalt will work with Enamine to take this programme forward.
Tokyo and Kyiv, Ukraine — 7 August 2026 — SyntheticGestalt, an AI technology pioneer dedicated to molecular AI, and Enamine, which has built the broadest, most synthetically accessible and most trusted chemical space, today announced a landmark collaboration to build the world’s largest in vitro-validated, AI-driven chemical data ecosystem.
Artificial intelligence has become a powerful tool in drug discovery, yet the high-quality data it needs to perform at its best remains in short supply. Enamine has assembled a curated database of billions of highly feasible REAL Compounds, and has brought its high-throughput synthesis capacity together with pharmacological and ADME/Tox testing in its proprietary B-REAL discovery platform. That combination has made data generation both fast and inexpensive. The two companies have now formed a strong partnership and, drawing on SyntheticGestalt’s advanced AI-driven predictive technology, aim to compress discovery timelines that traditionally ran for years into a matter of months.
Under the new collaboration, with strategic support from GENIAC (Generative AI Accelerator Challenge), a subsidy programme of Japan’s Ministry of Economy, Trade and Industry, and from the New Energy and Industrial Technology Development Organization (NEDO), SyntheticGestalt will analyse 100 industrially important protein targets and select candidate ligands for synthesis from REAL Compounds. Enamine will contribute the integrated capabilities of its B-REAL discovery platform, covering parallel synthesis, protein production, activity assays and preclinical in vitro validation under one roof. Unprecedented in scale and scope, the resulting dataset is scheduled for public release in 2027, and is expected to give the global scientific community, Japanese pharmaceutical partners first among them, a transformative resource for accelerating drug discovery and innovation.
Koki Shimada, CEO of SyntheticGestalt, said: “We founded SyntheticGestalt on a simple conviction: that AI will be the primary inventor of new molecules. This collaboration with Enamine turns that conviction into practice. By bringing together ZAO, the world’s largest molecular foundation model, and Enamine’s unmatched synthesis and validation capabilities, we will build a data ecosystem in which AI predictions are backed by experimental fact at unprecedented scale. We will generate hundreds of thousands of data points across 100 protein targets in high demand. Combining our technology with Enamine’s platform is intended to move AI from concept to practical use, and to reshape the molecular industry worldwide.”
“Enamine is proud to partner with SyntheticGestalt on this visionary initiative,” added Iaroslava Kos, Director, Business Development at Enamine. “This collaboration is a bold step, and one that redefines how AI and experimental science come together to open new frontiers in drug discovery. Together we will create a data ecosystem that puts unprecedented tools in the hands of Japanese researchers, drives innovation, and delivers solutions to pressing challenges in medicine and agriculture.”
“The strength of this partnership lies in the iterative synergy between AI and experiment. By grounding SyntheticGestalt’s predictions in Enamine’s rapid synthesis and rigorous biological validation, we are creating a validated ecosystem that accelerates the move from digital concept to tangible molecular leads,” emphasised Petro Borysko, Director of Biology at Enamine.
Dmytro Radchenko, Head of Parallel Chemistry at Enamine, said: “The true value of REAL Space lies in its immediate chemical accessibility and in the sheer throughput of parallel synthesis, which lets us produce thousands of novel compounds in a matter of weeks. Feeding that vast, tangible diversity into our shared data ecosystem means the billions of virtual possibilities generated by AI can be converted quickly, and at unprecedented scale, from digital ideas into physical molecules ready for experimental validation.”
About SyntheticGestalt
SyntheticGestalt KK is a molecular AI company based in Tokyo. It develops and deploys molecular AI for the pharmaceutical, chemical, materials, agrochemical, cosmetics and food industries, and since its founding in 2018 has pursued a single goal: to build systems that mass-produce invention through AI. Its research projects to date have identified pharmaceutical lead compounds and lower-impact materials, and in some projects have cut the cost and duration of discovery by up to 90% compared with conventional methods. For more information, visit https://www.syntheticgestalt.com.
About Enamine Ltd.
Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated drug discovery (IDD) with unique partnering opportunities in exploring new chemical spaces. The company combines access to in-house-produced screening compounds (4.8 million in stock) and building blocks (375,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate drug discovery efforts. https://enamine.net/
About Enamine REAL:
Enamine REAL (REadily AccessibLe) contains trillions of synthetically feasible molecules that can be synthesized at Enamine extremely fast (3-4 weeks), with high feasibility (over 80%), and inexpensive. The REAL Compounds are created by parallel chemistry through the compilation of 203K in-stock building blocks via 169 well-validated parallel synthesis protocols, underlying Enamine’s approach to design make-on-demand compounds to maximize synthesis success rate. For more information, visit: https://enamine.net/compound-collections/real-compounds
Note: References to the “world’s largest” data ecosystem in this release relate to the scale of in vitro-validated chemical data generated within a single project, based on SyntheticGestalt’s own research as of August 2026. ZAO is described as the “world’s largest” molecular foundation model on the basis of training scale — 10 billion compounds — compared with other publicly documented molecular foundation models as of the same date. The “up to 90%” reduction refers to results achieved in SyntheticGestalt’s past research projects; the actual reduction varies by target and conditions.
Media Enquiries
SyntheticGestalt KK
CEO Office, Sou Minakami
s.minakami@syntheticgestalt.com
